Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment

Respirology

Volumn 13, Issue 6, 2008, Pages 810-816

  Takahashi, Ken Ichi ^a   Chin, Kazuo ^a   Akamizu, Takashi ^b   Morita, Satoshi ^a   Sumi, Kensuke ^a   Oga, Toru ^a   Matsumoto, Hisako ^a   Niimi, Akio ^a   Tsuboi, Tomomasa ^c   Fukuhara, Shunichi ^a   Kangawa, Kenji ^b,d   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c National Hospital Organization Minami Kyoto Hospital   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Ghrelin; Growth hormone; Nasal CPAP; Obese; OSA

Indexed keywords

GHRELIN;

ACYLATION; ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; NOSE BREATHING; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; WEIGHT GAIN;

ACYLATION; ADULT; BODY MASS INDEX; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; OBESITY; SLEEP APNEA, OBSTRUCTIVE;

EID: 51349097403     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01357.x     Document Type: Article

References (34)

1. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005 365 : 1046 53.
2. Phillips BG, Hisel TM, Kato M, Pesek CA, Dyken ME et al. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J. Hypertens. 1999 17 : 1297 300.
3. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 2000 279 : 234 7.
4. Engleman HM, Asgari-Jirhandeh N, McLeod AL, Ramsay CF, Deary IJ et al. Self-reported use of CPAP and benefits of CPAP therapy: a patient survey. Chest 1996 109 : 1470 6.
5. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 : 656 60.
6. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H et al. A role for ghrelin in the central regulation of feeding. Nature 2001 409 : 194 8.
7. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J. Clin. Endocrinol. Metab. 2005 90 : 6 9.
8. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001 50 : 707 9.
9. Cassoni P, Papottti M, Ghe C, Catapano F, Sapino A et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 2001 86 : 1738 45.
10. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F et al. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur. J. Pharmacol. 2003 476 : 87 95.
11. Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 2004 145 : 234 42.
12. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli PA et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J. Clin. Endocrinol. Metab. 2004 89 : 3062 5.
13. Harsch IA, Konturek PC, Koebnick C, Kuehnlein PP, Fuchs FS et al. Leptin and ghrelin levels in patients with obstructive sleep apnea: effect of CPAP treatment. Eur. Respir. J. 2003 22 : 251 7.
14. Ulukavak CT, Kokturk O, Bukan N, Bilgihan A. Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration 2005 72 : 395 401.
15. Auwerx J, Steals B. Leptin. Lancet 1998 351 : 737 42.
16. Chin K, Shimizu K, Nakamura T, Narai N, Masuzaki H et al. Change in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999 100 : 706 12.
17. Sanner BM, Kollhosser P, Buechner N, Zideck W, Tepel M. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur. Respir. J. 2004 23 : 601 4.
18. Barcelo A, Barbe F, Llompart E, Pena M, Duran-cantolla J et al. Neurropeptide Y and leptin in patients with obstructive sleep apnea syndrome. Am. J. Respir. Crit. Care Med. 2005 171 : 183 7.
19. Chin K, Nakamura T, Takahashi K, Sumi K, Ogawa Y et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am. J. Med. 2003 114 : 370 6.
20. Phillips B, Kryger MH. Management of obstructive sleep apnea-hypopnea syndrome: overview. In : Kryger MH, Roth T, Dement WC (eds) Principles and Practice of Sleep Medicine. Elsevier Saunders, Philadelphia, PA, 2005 1109 21.
21. Li GW, Gavrila D, Liu X, Wang L, Gunnlaugsson S et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004 109 : 2221 6.
22. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest. 2004 114 : 57 66.
23. El Eter E, Al Tuwaijiri A, Hangar H, Arafa H. In vivo and in vitro antioxidant activity of ghrelin: attenuation of gastric ischemic injury in the rat. J. Gastroenterol. Hepatol. 2007 22 : 1791 9.
24. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003 290 : 1906 14.
25. Takahashi K-I, Chin K, Nakamura H, Morita S, Sumi K et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid. Redox Signal 2008 10 : 715 26.
26. Ryan S, Taylor CT, Mcnicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005 112 : 2660 7.
27. Mundinger TO, Cummings DE, Taborsky GJ Jr. Direct stimulation of ghrelin secretion by sympathetic nerves. Endocrinology 2006 147 : 2893 901.
28. Somers VK, Dyken ME, Clary MP, Abbound FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 1995 96 : 1897 904.
29. Hedner J, Ejnell H, Sellgren J, Hedner T, Wallin G. Is high and fluctuating muscle nerve sympathetic activity in the sleep apnoea syndrome of pathogenetic importance for the development of hypertension? J. Hypertens. 1988 6 (Suppl. 4 S529 31.
30. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993 103 : 1763 8.
31. Tschöp M, Flora DB, Wayer JP, Heiman ML. Hypophysectomy presents ghrelin-induced adiposity and increases gastric ghrelin secretion in rats. Obes. Res. 2002 10 : 991 9.
32. Grunstein RR. Hormonal and metabolic disturbances in sleep apnea. In : McNicholas WT, Phillipson EA (eds) Breathing Disorders in Sleep. W. B. Saunders, London, 2002 209 11.
33. Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D et al. Sleep apnea and sleep disruption in obese patients. Arch. Intern. Med. 1994 154 : 1705 11.
34. Wolk R, Shamsuzzaman AS, Somers VK. Obesity sleep apnea, and hypertension. Hypertension 2003 42 : 1067 74.